<a href="https://www.fiercebiotech.com/biotech/kura-posts-krazati-combo-data-drug-designed-unleash-kras-inhibitors-potential" hreflang="en">Kura posts Krazati combo data on drug designed to unleash KRAS inhibitors’ potential</a>
Kura Oncology has reported promising early data on its drug darlifarnib in combination with Bristol Myers Squibb's Krazati, showing response rates of up to 69% in patients with KRAS G12C-mutated solid tumors, particularly in pancreatic and non-small cell lung cancer. The combination demonstrated manageable safety and tolerability, although some colorectal cancer patients showed limited responses.
Kura Oncology's combination therapy of darlifarnib and Bristol Myers Squibb’s Krazati shows promising efficacy, achieving up to a 69% response rate in KRAS G12C-mutated solid tumors. This development highlights the potential of targeting persistent mTORC1 activity to overcome resistance in KRAS inhibitor treatments. For professionals in healthtech and biotech, these results signal a valuable opportunity to explore combination therapies as a strategy to enhance the effectiveness of current KRAS inhibitors, potentially impacting future clinical trial designs and investment decisions in precision oncology.